Research Analysts Offer Predictions for MDGL FY2025 Earnings

Key Points

• Cantor Fitzgerald has raised its FY2025 EPS estimate for Madrigal Pharmaceuticals from ($12.46) to ($6.98), indicating an expected improvement in earnings performance.
• The consensus estimate for Madrigal's current full-year earnings stands at ($23.47) per share, significantly below Cantor Fitzgerald's revised estimate.
• Madrigal Pharmaceuticals reported revenue of $212.80 million for the last quarter, surpassing expectations and showing a remarkable year-over-year growth of 1357.5%.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Equities researchers at Cantor Fitzgerald raised their FY2025 EPS estimates for shares of Madrigal Pharmaceuticals in a research report issued on Wednesday, August 6th. Cantor Fitzgerald analyst P. Agrawal now anticipates that the biopharmaceutical company will post earnings per share of ($6.98) for the year, up from their prior forecast of ($12.46). The consensus estimate for Madrigal Pharmaceuticals' current full-year earnings is ($23.47) per share. Cantor Fitzgerald also issued estimates for Madrigal Pharmaceuticals' FY2026 earnings at $3.96 EPS.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.90) EPS for the quarter, topping analysts' consensus estimates of ($3.48) by $1.58. Madrigal Pharmaceuticals had a negative net margin of 54.68% and a negative return on equity of 38.38%. The firm had revenue of $212.80 million during the quarter, compared to analysts' expectations of $158.94 million. During the same period in the previous year, the company earned ($7.10) EPS. The firm's revenue for the quarter was up 1357.5% compared to the same quarter last year.

MDGL has been the subject of several other reports. JMP Securities reissued a "market outperform" rating and issued a $443.00 price objective on shares of Madrigal Pharmaceuticals in a research report on Thursday, April 24th. Wall Street Zen upgraded shares of Madrigal Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Monday, May 5th. UBS Group restated a "buy" rating and issued a $523.00 price target (up previously from $458.00) on shares of Madrigal Pharmaceuticals in a report on Tuesday. Canaccord Genuity Group boosted their price target on shares of Madrigal Pharmaceuticals from $420.00 to $428.00 and gave the company a "buy" rating in a report on Wednesday, August 6th. Finally, B. Riley restated a "buy" rating and issued a $460.00 price target (up previously from $422.00) on shares of Madrigal Pharmaceuticals in a report on Friday, May 2nd. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $439.71.

Madrigal Pharmaceuticals Trading Up 2.5%

Shares of MDGL stock traded up $8.67 during trading hours on Friday, reaching $358.17. 359,213 shares of the stock were exchanged, compared to its average volume of 375,339. The firm has a market capitalization of $7.95 billion, a price-to-earnings ratio of -27.90 and a beta of -1.02. The company has a current ratio of 5.11, a quick ratio of 4.78 and a debt-to-equity ratio of 0.17. Madrigal Pharmaceuticals has a 12-month low of $200.63 and a 12-month high of $377.46. The company's 50-day moving average price is $303.20 and its 200-day moving average price is $312.98.

Insider Activity at Madrigal Pharmaceuticals

In related news, Director Rebecca Taub sold 26,444 shares of the business's stock in a transaction that occurred on Wednesday, July 16th. The shares were sold at an average price of $353.47, for a total transaction of $9,347,160.68. Following the completion of the transaction, the director owned 461,044 shares in the company, valued at $162,965,222.68. The trade was a 5.42% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Paul A. Friedman sold 26,176 shares of the business's stock in a transaction that occurred on Wednesday, July 16th. The stock was sold at an average price of $353.47, for a total transaction of $9,252,430.72. Following the transaction, the director owned 187,164 shares of the company's stock, valued at approximately $66,156,859.08. This trade represents a 12.27% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 60,377 shares of company stock valued at $21,316,969. 21.50% of the stock is currently owned by company insiders.

Institutional Trading of Madrigal Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Paulson & CO. Inc. grew its position in Madrigal Pharmaceuticals by 2.8% during the 1st quarter. Paulson & CO. Inc. now owns 2,099,523 shares of the biopharmaceutical company's stock worth $695,425,000 after purchasing an additional 57,523 shares during the last quarter. FMR LLC boosted its holdings in shares of Madrigal Pharmaceuticals by 10.8% in the 4th quarter. FMR LLC now owns 867,850 shares of the biopharmaceutical company's stock valued at $267,792,000 after acquiring an additional 84,305 shares during the last quarter. Woodline Partners LP boosted its holdings in shares of Madrigal Pharmaceuticals by 2.7% in the 1st quarter. Woodline Partners LP now owns 317,433 shares of the biopharmaceutical company's stock valued at $105,143,000 after acquiring an additional 8,316 shares during the last quarter. Rock Springs Capital Management LP boosted its holdings in shares of Madrigal Pharmaceuticals by 0.8% in the 4th quarter. Rock Springs Capital Management LP now owns 265,212 shares of the biopharmaceutical company's stock valued at $81,836,000 after acquiring an additional 2,150 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Madrigal Pharmaceuticals by 1.4% in the 4th quarter. Bank of America Corp DE now owns 217,828 shares of the biopharmaceutical company's stock valued at $67,215,000 after acquiring an additional 2,940 shares during the last quarter. Hedge funds and other institutional investors own 98.50% of the company's stock.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.